These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 33609924)

  • 1. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Ma J; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 Oct; 55():103181. PubMed ID: 34365314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
    Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y
    BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
    Casallas-Vanegas A; Gomez-Figueroa E; de Saráchaga AJ; Zabala-Angeles I; García-Estrada C; Salado-Burbano JC; DiazGranados-Palacio MC; Corona-Vázquez T; de Jesús Flores-Rivera J; Rivas-Alonso V
    J Neurol Sci; 2020 Dec; 419():117204. PubMed ID: 33161302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.
    Damato V; Evoli A; Iorio R
    JAMA Neurol; 2016 Nov; 73(11):1342-1348. PubMed ID: 27668357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    Spagni G; Sun B; Monte G; Sechi E; Iorio R; Evoli A; Damato V
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):62-69. PubMed ID: 36283808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.
    Dong GY; Meng YH; Xiao XJ
    Medicine (Baltimore); 2022 Sep; 101(36):e30347. PubMed ID: 36086713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
    J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis.
    Han M; Chen Y; Nong L; Liu Z; Hao L; Wang Z
    Medicine (Baltimore); 2020 Jul; 99(28):e21067. PubMed ID: 32664124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders.
    Xie Q; Zheng T; Sun M; Sun J; Wang M
    Mult Scler Relat Disord; 2020 Oct; 45():102421. PubMed ID: 32731203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
    Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
    J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis.
    Huang W; Wang L; Zhang B; Zhou L; Zhang T; Quan C
    Mult Scler Relat Disord; 2019 Oct; 35():246-252. PubMed ID: 31425902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.